News: PRR Prima BioMed says clinical studies of IMP321 are progressing well, page-17

Ahjay,
Another policy intended to speed up the timeline to approval is the expansion of China’s fast-track pathway. Previously the pathway, known as the "green channel," was available for drugs that have not been marketed anywhere in the world. The CFDA expanded the pathway to allow more types of drugs to access the green channel, said Wang.

For example, drugs that target high unmet needs in China, innovative drugs using advanced technology, imported innovative drugs manufactured in China, as well as pediatric and geriatric drugs, to name a few, all have access to the green channel.